Tonix Pharmaceuticals (NASDAQ:TNXP) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report released on Sunday. The brokerage issued a sell rating on the stock.

Tonix Pharmaceuticals Trading Up 5.1 %

NASDAQ:TNXP opened at $0.24 on Friday. The company has a market capitalization of $44.95 million, a PE ratio of 0.00 and a beta of 2.23. Tonix Pharmaceuticals has a 52-week low of $0.12 and a 52-week high of $22.14. The stock has a fifty day simple moving average of $0.17 and a 200-day simple moving average of $0.59. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $1.80. The firm had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, equities research analysts expect that Tonix Pharmaceuticals will post -17.63 earnings per share for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.